pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-488 |
Genomic Coordinates | chr1: 177029363 - 177029445 |
Synonyms | MIRN488, hsa-mir-488, MIR488 |
Description | Homo sapiens miR-488 stem-loop |
Comment | miR-488-3p cloned in has a 1 nt 3' extension (U), which is incompatible with the genome sequence. |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-488-3p | |||||||||||||||||||||
Sequence | 52| UUGAAAGGCUAUUUCUUGGUC |72 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | Cloned | |||||||||||||||||||||
Editing Events in miRNAs |
|
DRVs in miRNA |
|
|||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SLC39A8 | ||||||||||||||||||||
Synonyms | BIGM103, CDG2N, LZT-Hs6, PP3105, ZIP8 | ||||||||||||||||||||
Description | solute carrier family 39 member 8 | ||||||||||||||||||||
Transcript | NM_001135147 | ||||||||||||||||||||
Other Transcripts | NM_001135146 , NM_001135148 , NM_022154 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SLC39A8 | |||||||||||||||||||||
3'UTR of SLC39A8 (miRNA target sites are highlighted) |
>SLC39A8|NM_001135147|3'UTR 1 TAATTTCATTATCTGGAGTATTTCACCTCCACATCTCTGCAATACCAGCACCTTCAACAGTGATTGGTTAGAGGTTGGCA 81 TATGACATAGTTATGACCATTGAGACGTGATGCTGTGTGTGCTGTGAAGTTTCTCAAAAGGAGTAAGGAAGATACAGCCT 161 CTTCTTTCTAGGGACTTTGTTTGTAGGTGTGACACCTGGAGCAGCCATTTTGCTACTGTTTTGTTTCTAATTGTGTTCCC 241 CGCCGCCCTCCCCGCTCGCCCCGAAAAACGACATGTTTGAGTTCTAATCCCCAGTATTTCAGAATGTGACCTTATTTGGA 321 AATAGAGTCATTGCAAATGTAATTTGTTAAGATGAGCTCATACTGGAGTAGAGTGGGTTCCTGATCTAGTATGACTGGTA 401 TTCTTATTAAAAAGAGAAATTTGAATACTAGCTACACCATGTAAAGATGAAGGCAGAGATCGTGGTGATGCATCTACAAT 481 GTCAACAATTGCCAGCAAATCATCAGAATCTGGGAGAGAGGTATGGAATGAATTCTCTCTCGCAGCCCTAAGAAGGAACC 561 AATCCTGTGCACACCTGAATCTTGGACTTCCAGCCTCCACAACTGTGAGACAATACATTTTTGTTATTTAAGCTACCCAG 641 TTGTGGCACTTTATTACTGCAGTTCTAGCCGACTAATACAGCTACCTTGAGAGGAAATAGCATGGGGATGAAGGTGATGT 721 GCTGAAGAAGCACAGCAGAAAGTGGAAAGATGGTCCATGAGGACATCCTTAGCCACTGAATTGACAAGCCTCTTCCCTGG 801 AGTCCCTCTTCCTTGGGATTTTTTTTGGTGTGTGTAATAATCACTTTTCCTAATGGTGCAAACCATTGTGAGTTGCTCTT 881 TGACTGCTAGTAATTAAAGCAAACTAACCAAGTCAGCCCTCCCCAGTGTTCCTTTTTGCAATCTAAATTCTGATGTCCAA 961 CTCCTCCCTGGGCCACTCCCTGTCCCCAGATGTCTCTTTGTATATCTAAAGAAGAAAAAGAAGGATAAATCCTTTTTCTC 1041 CCAAGAGATCTCCCTGCTTTTGTGAAAAGCACAAAGAAGGGCATTATCTAACTTTTCTCATCATTAGAAGTCAAGCCTGG 1121 CCGTGACTCCCGTTATGACATTTTGATGGCCACATTTTATGAGAAAAGCCCAAACAGACAGACCTGTCTGTAAATTCTTT 1201 CATCCTTTGCATTCTTTCTTTGACTGTACCTTAGAGAGTGTTTGATTATTGCAGGGGAGATGGAAAAGAAGCAGGTTCTG 1281 GCCTATGCTCTAGTTCCTCACTTTCTGGAGTTATCTTTTGGGCCTGGAGTCTCTTGGAGTGAGGAAAGGAAGCCATTTTT 1361 ATACTTTACTTATGGTAGAGTTAAACTTCGTACTCTTAGGAGGCTACATGCAATCTCCAAGAGGAAGAGAGTGAAGAGGT 1441 TAAGAATTATGCCATCAAAATGTGCTGCTCTGGCATATTGACTATTTGAATTACAGATATTTTAAAAACATCAGATATGA 1521 AGAGGTCACTCTGATCTTAATTCTGTGTCTTAACAGCAGGAGATGAAATTCCCACATGGGAGATGGCCTCCCTGTCACAG 1601 AAGGAATACCATTCTCCCTATCAATGATGAGAAATTGGAACTGAGAGAATTCTGTATAGACCTTGTTCAAGTAATTCTTC 1681 TATTTTAAACCTCCCCACATAATTTAGCTGCCTTTTCAAAACTACTGTCCTTTGTGCAACCAGTATAGAAGCGATTGACT 1761 CTCACTGCATCCTTGGGTCTTCTTTTCCCTATATGGGCTCTTTTCCCATATGGGCTCTTATGTCCTGTAAAACATGTATT 1841 AAATAAATTTGTATGCTTTTCTCCCGTTAACCTGTCTTACATCAATTTAATTCTTGGGCCCAGGTAGGACCCTAAGAGGA 1921 CAGAGGTCGAGTTTTGCCACCTCTGCAAGAGAAAAGAGAGATGCCCAGACCACCAGGCCTGGGAAATCTTTGATTTCCCA 2001 GGCTTTGAAGTGGGCACTGTGTCTGAACCTGGCCCTCTGAAACTTCCTGTTCCTGGACATCCCAGCTGCTAATGTGAGTT 2081 GCCCTTGCACTGGCTCAGGGCTGGGACATTAAAGGAATTTCCCTTTTGTTGACATAACAGTAGGATGGCTATAGCTAACA 2161 ATAATATATTATTTAGTTTCAAGTAGCTAGAAGGAACATATGAATGTTCCCAACACAAAGAAATGACAACTATTTGAGAT 2241 GATGGATATGCTAATAACCTTAATCTGATTCCTATACATTATATGCATCACATATACATACATTATATGTATAACATCAC 2321 TATGTACCCCATAAATATGTGCAATTATTGTCAATTAAACAAATAAATTTAAACAAACATTAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | unspecified |
Disease | 64116.0 |
Location of target site | 3'UTR |
Tools used in this research | unspecified |
Original Description (Extracted from the article) |
...
"As seen in Figure 3D
... - Song J; Kim D; Lee CH; Lee MS; Chun CH; Jin EJ, 2013, Journal of biomedical science. |
Article |
- Song J; Kim D; Lee CH; Lee MS; Chun CH; Jin EJ - Journal of biomedical science, 2013
BACKGROUND: Even though osteoarthritis (OA) is the most common musculoskeletal dysfunction, there are no effective pharmacological treatments to treat OA due to lack of understanding in OA pathology. To better understand the mechanism in OA pathogenesis and investigate its effective target, we analyzed miRNA profiles during OA pathogenesis and verify the role and its functional targets of miR-488. RESULTS: Human articular chondrocytes were obtained from cartilage of OA patients undergoing knee replacement surgery and biopsy samples of normal cartilage and the expression profile of miRNA was analyzed. From expression profile, most potent miR was selected and its target and functional role in OA pathogenesis were investigated using target validation system and OA animal model system. Among miRNAs tested, miR-488 was significantly decreased in OA chondrocytes Furthermore, we found that exposure of IL-1beta was also suppressed whereas exposure of TGF-beta3 induced the induction of miR-488 in human articular chondrocytes isolated from biopsy samples of normal cartilages. Target validation study showed that miR-488 targets ZIP8 and suppression of ZIP8 in OA animal model showed the reduced cartilage degradation. Target validation study showed that miR-488 targets ZIP8 and suppression of ZIP8 in OA animal model showed the reduced cartilage degradation. CONCLUSIONS: miR-488 acts as a positive role for chondrocyte differentiation/cartilage development by inhibiting MMP-13 activity through targeting ZIP-8.
LinkOut: [PMID: 23688035]
|
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
116 hsa-miR-488-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT005899 | POMC | proopiomelanocortin | 3 | 1 | ||||||||
MIRT038008 | CYP2E1 | cytochrome P450 family 2 subfamily E member 1 | 1 | 1 | ||||||||
MIRT054483 | SLC39A8 | solute carrier family 39 member 8 | 2 | 1 | ||||||||
MIRT058884 | C11ORF58 | chromosome 11 open reading frame 58 | 2 | 2 | ||||||||
MIRT061194 | MED17 | mediator complex subunit 17 | 2 | 2 | ||||||||
MIRT167237 | TMEM167A | transmembrane protein 167A | 2 | 2 | ||||||||
MIRT188343 | ARID1A | AT-rich interaction domain 1A | 2 | 2 | ||||||||
MIRT218170 | MRPL18 | mitochondrial ribosomal protein L18 | 2 | 2 | ||||||||
MIRT218297 | C6ORF120 | chromosome 6 open reading frame 120 | 2 | 2 | ||||||||
MIRT263337 | ANAPC16 | anaphase promoting complex subunit 16 | 2 | 2 | ||||||||
MIRT294633 | ZNF548 | zinc finger protein 548 | 2 | 2 | ||||||||
MIRT305053 | SRPRB | SRP receptor beta subunit | 2 | 6 | ||||||||
MIRT306846 | FYTTD1 | forty-two-three domain containing 1 | 2 | 2 | ||||||||
MIRT442753 | NRIP3 | nuclear receptor interacting protein 3 | 2 | 2 | ||||||||
MIRT443955 | S1PR2 | sphingosine-1-phosphate receptor 2 | 2 | 2 | ||||||||
MIRT444032 | SYNM | synemin | 2 | 2 | ||||||||
MIRT444519 | WWTR1 | WW domain containing transcription regulator 1 | 2 | 2 | ||||||||
MIRT444569 | UNC5C | unc-5 netrin receptor C | 2 | 2 | ||||||||
MIRT444779 | ECE1 | endothelin converting enzyme 1 | 2 | 2 | ||||||||
MIRT445195 | FAXC | failed axon connections homolog | 2 | 2 | ||||||||
MIRT445345 | FAM169A | family with sequence similarity 169 member A | 2 | 2 | ||||||||
MIRT445539 | TBC1D8 | TBC1 domain family member 8 | 2 | 2 | ||||||||
MIRT446058 | RABIF | RAB interacting factor | 2 | 2 | ||||||||
MIRT446358 | EFCAB6 | EF-hand calcium binding domain 6 | 2 | 2 | ||||||||
MIRT446486 | PRELP | proline and arginine rich end leucine rich repeat protein | 2 | 2 | ||||||||
MIRT446973 | CARKD | NAD(P)HX dehydratase | 2 | 2 | ||||||||
MIRT446984 | MOB1B | MOB kinase activator 1B | 2 | 2 | ||||||||
MIRT446987 | TMEM9B | TMEM9 domain family member B | 2 | 2 | ||||||||
MIRT447376 | AGPAT5 | 1-acylglycerol-3-phosphate O-acyltransferase 5 | 2 | 2 | ||||||||
MIRT447857 | MLLT1 | MLLT1, super elongation complex subunit | 2 | 2 | ||||||||
MIRT448077 | BRMS1L | breast cancer metastasis-suppressor 1 like | 2 | 2 | ||||||||
MIRT448970 | CBX5 | chromobox 5 | 2 | 2 | ||||||||
MIRT449072 | RPS15A | ribosomal protein S15a | 2 | 2 | ||||||||
MIRT449200 | PTPLAD2 | 3-hydroxyacyl-CoA dehydratase 4 | 1 | 1 | ||||||||
MIRT449459 | HAT1 | histone acetyltransferase 1 | 2 | 2 | ||||||||
MIRT449588 | PCDHA6 | protocadherin alpha 6 | 2 | 2 | ||||||||
MIRT449885 | ZNF621 | zinc finger protein 621 | 2 | 2 | ||||||||
MIRT449892 | C11orf34 | placenta expressed transcript 1 | 1 | 2 | ||||||||
MIRT450669 | SGIP1 | SH3 domain GRB2 like endophilin interacting protein 1 | 2 | 2 | ||||||||
MIRT450866 | GPR107 | G protein-coupled receptor 107 | 2 | 2 | ||||||||
MIRT450881 | EIF6 | eukaryotic translation initiation factor 6 | 2 | 2 | ||||||||
MIRT455373 | AAED1 | AhpC/TSA antioxidant enzyme domain containing 1 | 2 | 2 | ||||||||
MIRT458266 | FUT10 | fucosyltransferase 10 | 2 | 2 | ||||||||
MIRT464839 | RPS27A | ribosomal protein S27a | 2 | 12 | ||||||||
MIRT465335 | TPM3 | tropomyosin 3 | 2 | 4 | ||||||||
MIRT467939 | SLC16A1 | solute carrier family 16 member 1 | 2 | 2 | ||||||||
MIRT468719 | SDC4 | syndecan 4 | 2 | 2 | ||||||||
MIRT469844 | PXK | PX domain containing serine/threonine kinase like | 2 | 8 | ||||||||
MIRT474545 | KLHDC3 | kelch domain containing 3 | 2 | 2 | ||||||||
MIRT480700 | BRPF1 | bromodomain and PHD finger containing 1 | 2 | 2 | ||||||||
MIRT482087 | ALG8 | ALG8, alpha-1,3-glucosyltransferase | 2 | 2 | ||||||||
MIRT491225 | KCNA5 | potassium voltage-gated channel subfamily A member 5 | 2 | 2 | ||||||||
MIRT497790 | DTX3L | deltex E3 ubiquitin ligase 3L | 2 | 2 | ||||||||
MIRT497831 | GPR26 | G protein-coupled receptor 26 | 2 | 2 | ||||||||
MIRT497910 | HERC2 | HECT and RLD domain containing E3 ubiquitin protein ligase 2 | 2 | 2 | ||||||||
MIRT498428 | DDX39A | DExD-box helicase 39A | 2 | 2 | ||||||||
MIRT499196 | TJAP1 | tight junction associated protein 1 | 2 | 2 | ||||||||
MIRT500396 | ZNF281 | zinc finger protein 281 | 2 | 6 | ||||||||
MIRT501523 | PPP1R15B | protein phosphatase 1 regulatory subunit 15B | 2 | 10 | ||||||||
MIRT504445 | MC2R | melanocortin 2 receptor | 2 | 2 | ||||||||
MIRT505270 | TUBB2A | tubulin beta 2A class IIa | 2 | 2 | ||||||||
MIRT508584 | CCDC115 | coiled-coil domain containing 115 | 2 | 12 | ||||||||
MIRT509269 | NPM3 | nucleophosmin/nucleoplasmin 3 | 2 | 4 | ||||||||
MIRT512466 | CCDC149 | coiled-coil domain containing 149 | 2 | 2 | ||||||||
MIRT513534 | PRDM2 | PR/SET domain 2 | 2 | 4 | ||||||||
MIRT514218 | ZNF83 | zinc finger protein 83 | 2 | 4 | ||||||||
MIRT518526 | FLCN | folliculin | 2 | 6 | ||||||||
MIRT524841 | ARPP19 | cAMP regulated phosphoprotein 19 | 2 | 2 | ||||||||
MIRT524855 | ARL5B | ADP ribosylation factor like GTPase 5B | 2 | 4 | ||||||||
MIRT525048 | FRK | fyn related Src family tyrosine kinase | 2 | 2 | ||||||||
MIRT528635 | SENP6 | SUMO1/sentrin specific peptidase 6 | 2 | 2 | ||||||||
MIRT529557 | SNRNP48 | small nuclear ribonucleoprotein U11/U12 subunit 48 | 2 | 2 | ||||||||
MIRT532319 | GHSR | growth hormone secretagogue receptor | 2 | 2 | ||||||||
MIRT534232 | SLC25A16 | solute carrier family 25 member 16 | 2 | 2 | ||||||||
MIRT534254 | SLC12A7 | solute carrier family 12 member 7 | 2 | 2 | ||||||||
MIRT536223 | LRRC41 | leucine rich repeat containing 41 | 2 | 2 | ||||||||
MIRT537658 | ERBB2IP | erbb2 interacting protein | 2 | 2 | ||||||||
MIRT537795 | EIF1AX | eukaryotic translation initiation factor 1A, X-linked | 2 | 2 | ||||||||
MIRT540404 | PITPNC1 | phosphatidylinositol transfer protein, cytoplasmic 1 | 2 | 2 | ||||||||
MIRT544563 | POLDIP3 | DNA polymerase delta interacting protein 3 | 2 | 2 | ||||||||
MIRT546045 | VPS4B | vacuolar protein sorting 4 homolog B | 2 | 2 | ||||||||
MIRT546846 | RAB4A | RAB4A, member RAS oncogene family | 2 | 2 | ||||||||
MIRT548480 | EEF2 | eukaryotic translation elongation factor 2 | 2 | 2 | ||||||||
MIRT549337 | ARF6 | ADP ribosylation factor 6 | 2 | 2 | ||||||||
MIRT550855 | SNAP47 | synaptosome associated protein 47 | 2 | 4 | ||||||||
MIRT551607 | ZNF267 | zinc finger protein 267 | 2 | 2 | ||||||||
MIRT553222 | TWF1 | twinfilin actin binding protein 1 | 2 | 2 | ||||||||
MIRT553874 | SUPT7L | SPT7 like, STAGA complex gamma subunit | 2 | 4 | ||||||||
MIRT557956 | FAM222B | family with sequence similarity 222 member B | 2 | 2 | ||||||||
MIRT559264 | BAG4 | BCL2 associated athanogene 4 | 2 | 4 | ||||||||
MIRT562245 | GRWD1 | glutamate rich WD repeat containing 1 | 2 | 2 | ||||||||
MIRT563184 | YDJC | YdjC chitooligosaccharide deacetylase homolog | 2 | 2 | ||||||||
MIRT563834 | SMDT1 | single-pass membrane protein with aspartate rich tail 1 | 2 | 2 | ||||||||
MIRT563967 | RAB6A | RAB6A, member RAS oncogene family | 2 | 2 | ||||||||
MIRT564808 | ZBTB21 | zinc finger and BTB domain containing 21 | 2 | 2 | ||||||||
MIRT565188 | TSHZ1 | teashirt zinc finger homeobox 1 | 2 | 2 | ||||||||
MIRT565549 | SMG1 | SMG1, nonsense mediated mRNA decay associated PI3K related kinase | 2 | 2 | ||||||||
MIRT566969 | LBR | lamin B receptor | 2 | 2 | ||||||||
MIRT570926 | ZNF284 | zinc finger protein 284 | 2 | 2 | ||||||||
MIRT612283 | ZMAT3 | zinc finger matrin-type 3 | 2 | 2 | ||||||||
MIRT612695 | PKNOX1 | PBX/knotted 1 homeobox 1 | 2 | 2 | ||||||||
MIRT625293 | ZNF619 | zinc finger protein 619 | 2 | 2 | ||||||||
MIRT628496 | LINS | lines homolog 1 | 2 | 2 | ||||||||
MIRT640282 | FAM169B | family with sequence similarity 169 member B | 2 | 2 | ||||||||
MIRT647212 | CYP2U1 | cytochrome P450 family 2 subfamily U member 1 | 2 | 2 | ||||||||
MIRT654668 | PSMB5 | proteasome subunit beta 5 | 2 | 2 | ||||||||
MIRT657516 | HAS2 | hyaluronan synthase 2 | 2 | 2 | ||||||||
MIRT670337 | C1orf106 | chromosome 1 open reading frame 106 | 2 | 4 | ||||||||
MIRT702010 | MIDN | midnolin | 2 | 2 | ||||||||
MIRT704253 | DHCR24 | 24-dehydrocholesterol reductase | 2 | 2 | ||||||||
MIRT710205 | ENAH | ENAH, actin regulator | 2 | 2 | ||||||||
MIRT712126 | TGFBR2 | transforming growth factor beta receptor 2 | 2 | 2 | ||||||||
MIRT714890 | COQ10B | coenzyme Q10B | 2 | 2 | ||||||||
MIRT716588 | PAX6 | paired box 6 | 2 | 2 | ||||||||
MIRT720810 | CIAO1 | cytosolic iron-sulfur assembly component 1 | 2 | 2 | ||||||||
MIRT724953 | AHCY | adenosylhomocysteinase | 2 | 2 |
miRNA-Drug Associations | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|